Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 21Thoracic 8Genitourinary 8Gynecologic 4Other solid neoplasm 3Tumor-Agnostic 2Gastrointestinal 1CNS 1

Conditions

Solid Tumor 1Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × sacituzumab govitecan × Other solid neoplasm × Clear all
NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Gilead Sciences

Phase 2 Active not recruiting
53 enrolled
Other solid neoplasm

Solid Tumor

NCT04319198 2025-09-30

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Gilead Sciences

Phase 4 Completed
25 enrolled 15 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡